CoChat

Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

Hampel, Harald, Lista, Simone, Khachaturian, Zaven S. · 2012 · Alzheimer's & Dementia
Cited by 135

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

The aim of this perspective article is to stimulate radical shifts in thinking and foster further discussion on the effective discovery, development, validation, and qualification process of biological markers derived from all available technical modalities that meet the complex conceptual and pathophysiological challenges across all stages of the complex, nonlinear, dynamic, and chronically progressive sporadic Alzheimer's disease (AD). This perspective evaluates the current state of the science regarding a broad spectrum of hypothesis‐driven and exploratory technologies and “markers” as candidates for all required biomarker functions, in particular, surrogate indicators of adaptive to maladaptive and compensatory to decompensatory, reversible to irreversible brain “systems failure.” We stress the future importance of the systems biology (SB) paradigm (next to the neural network paradigm) for substantial progress in AD research. SB represents an integrated and deeper investigation of interacting biomolecules within cells and organisms. This approach has only recently become feasible as high‐throughput technologies and mass spectrometric analyses of proteins and lipids, together with rigorous bioinformatics, have evolved. Existing high‐content data derived from clinically and experimentally derived neural tissues point to convergent pathophysiological pathways during the course of AD, transcending traditional descriptive studies to reach a more integrated and comprehensive understanding of AD pathophysiology, derived systems biomarkers, and “druggable” system nodes. The discussion is continued on the premise that the lack of integration of advanced biomarker technologies and transfertilization from more mature translational research fields (e.g., oncology, immunology, cardiovascular), which satisfy regulatory requirements for an accurate, sensitive, and well‐validated surrogate marker of specific pathophysiological processes and/or clinical outcomes, is a major rate‐limiting factor for the successful development and approval of effective treatments for AD prevention. We consider the conceptual, scientific, and technical challenges for the discovery‐development‐validation‐qualification process of biomarker tools and analytical algorithms for detection of the earliest pathophysiological processes in asymptomatic individuals at elevated risk during preclinical stages of AD. The most critical need for rapid translation of putative markers into validated (performance) and standardized (harmonized standard operating procedures) biomarker tools that fulfill regulatory requirements (qualify for use in treatment trials: e.g., safety, target engagement, mechanism of action, enrichment, stratification, secondary and primary outcome, surrogate outcome) is the availability of a large‐scale worldwide comprehensive longitudinal database that includes the following cohorts: (a) healthy aging, (b) people at elevated risks (genetic/epigenetic/lifestyle/comorbid conditions), and (c) asymptomatic–preclinical/prodromal–mild cognitive impairment/syndromal mild, moderate, or severe AD. Our proposal, as initial strategic steps for integrating markers into future development of diagnostic and therapy trial technologies, is to work toward: (a) creating the essential research and development infrastructure as an international shared resource, (b) building the organizational structure for managing such a multinational shared resource, and (c) establishing an integrated transsectoral multidisciplinary global network of collaborating investigators to help build and use the shared research resource.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.05.2116

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 112

  1. 10.1016/j.pneurobio.2011.09.004 · DOI
  2. 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
  3. 10.1212/WNL.34.7.939 · DOI · Paper page
  4. 10.1016/j.jalz.2011.03.005 · DOI · Paper page
  5. 10.1186/1750-1326-4-19 · DOI · Paper page
  6. 10.1016/j.pneurobio.2011.08.014 · DOI
  7. 10.1007/BF03256398 · DOI
  8. Thomas L, 2007, Labor und diagnose
  9. 10.1007/s12603-009-0036-7 · DOI
  10. 10.1038/nrd3115 · DOI · Paper page
  11. 10.1038/nrd1130 · DOI · Paper page
  12. 10.1067/mcp.2001.113989 · DOI · Paper page
  13. 10.1111/j.1755-5949.2009.00104.x · DOI · Paper page
  14. 10.1016/j.pneurobio.2011.07.004 · DOI · Paper page
  15. 10.1016/j.pneurobio.2011.07.008 · DOI
  16. Bertram L, 2011, The role of genetics for biomarker development in neurodegeneration, Prog Neurobiol, 95, 501, 10.1016/j.pneurobio.2011.09.011 · DOI
  17. 10.1016/j.pneurobio.2011.11.008 · DOI · Paper page
  18. 10.1523/JNEUROSCI.4521-10.2010 · DOI · Paper page
  19. 10.1002/ana.22365 · DOI · Paper page
  20. 10.1002/ana.20009 · DOI · Paper page
  21. 10.1016/j.biopsych.2010.05.013 · DOI · Paper page
  22. Hampel H. Amyloid‐β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. J Alzheimers Dis (in press).
  23. 10.1016/j.neurobiolaging.2010.04.013 · DOI · Paper page
  24. 10.1093/brain/awl051 · DOI · Paper page
  25. 10.1148/radiol.10091402 · DOI · Paper page
  26. 10.1016/j.tins.2011.05.005 · DOI · Paper page
  27. 10.1212/WNL.0b013e3182563bbe · DOI · Paper page
  28. 10.1196/annals.1427.007 · DOI · Paper page
  29. 10.1212/01.WNL.0000147469.18313.3B · DOI · Paper page
  30. 10.1212/WNL.0b013e3181b23564 · DOI · Paper page
  31. 10.1212/WNL.0b013e31820af94e · DOI · Paper page
  32. 10.1136/jnnp.2007.124149 · DOI · Paper page
  33. 10.1016/j.pneurobio.2011.11.009 · DOI
  34. 10.1007/s12603-012-0044-x · DOI · Paper page
  35. 10.1007/s12603-012-0021-4 · DOI
  36. 10.1016/j.jalz.2007.08.006 · DOI · Paper page
  37. 10.1016/S0304-3940(00)01697-9 · DOI · Paper page
  38. 10.1016/j.expneurol.2009.09.024 · DOI · Paper page
  39. 10.1602/neurorx.1.2.213 · DOI · Paper page
  40. 10.1016/j.jalz.2011.09.172 · DOI · Paper page
  41. 10.1001/archneurol.2011.183 · DOI · Paper page
  42. 10.1016/S0014-4886(03)00027-X · DOI
  43. 10.1038/mp.2008.84 · DOI · Paper page
  44. 10.1002/ana.20144 · DOI
  45. 10.1212/01.wnl.0000229925.52203.4c · DOI · Paper page
  46. 10.1373/clinchem.2006.066720 · DOI · Paper page
  47. 10.1080/00365510701864610 · DOI · Paper page
  48. 10.1523/JNEUROSCI.3916-08.2008 · DOI · Paper page
  49. 10.3233/JAD-2012-111361 · DOI · Paper page
  50. CLMasters DJSelkoe.Biochemistry of amyloid β‐protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med(in press).
  51. 10.1038/nm.2221 · DOI
  52. 10.1016/j.molmed.2006.10.002 · DOI
  53. 10.1523/JNEUROSCI.4580-03.2004 · DOI · Paper page
  54. 10.3233/JAD-2010-1253 · DOI · Paper page
  55. 10.1016/S0006-8993(99)01146-4 · DOI
  56. 10.1016/S0006-8993(97)01355-3 · DOI
  57. 10.1371/journal.pone.0016032 · DOI · Paper page
  58. 10.1371/journal.pone.0018850 · DOI · Paper page
  59. 10.1002/ana.22448 · DOI · Paper page
  60. 10.1212/WNL.0b013e318248e568 · DOI · Paper page
  61. 10.1007/s00702-003-0065-z · DOI
  62. 10.1038/mp.2008.96 · DOI · Paper page
  63. 10.1602/neurorx.1.2.226 · DOI · Paper page
  64. 10.1038/nm1635 · DOI · Paper page
  65. 10.3233/JAD-2011-111421 · DOI · Paper page
  66. 10.1001/archneurol.2008.565 · DOI · Paper page
  67. 10.1212/WNL.57.12.2243 · DOI
  68. 10.1001/archneur.59.1.71 · DOI · Paper page
  69. 10.1016/S0197-4580(01)00340-2 · DOI · Paper page
  70. 10.1001/archneur.59.6.972 · DOI · Paper page
  71. 10.1002/ana.10272 · DOI · Paper page
  72. 10.1038/nature01325 · DOI · Paper page
  73. 10.1001/archneurol.2010.215 · DOI · Paper page
  74. 10.1007/978-3-0348-8350-4_6 · DOI
  75. 10.1007/s00406-004-0558-2 · DOI
  76. 10.1016/S0304-3940(97)00379-0 · DOI
  77. 10.1016/S0006-8993(97)01355-3 · DOI
  78. 10.1007/s00406-003-0405-x · DOI
  79. 10.1016/j.biopsych.2009.01.032 · DOI
  80. 10.1001/archneurol.2008.530 · DOI · Paper page
  81. 10.1093/brain/awl279 · DOI · Paper page
  82. 10.1371/journal.pone.0028527 · DOI · Paper page
  83. 10.1586/14789450.4.2.227 · DOI · Paper page
  84. 10.1371/journal.pone.0031501 · DOI · Paper page
  85. 10.1016/j.tins.2008.10.003 · DOI
  86. 10.1038/35015709 · DOI · Paper page
  87. 10.1038/nature01510 · DOI · Paper page
  88. 10.1016/j.semcancer.2006.03.005 · DOI · Paper page
  89. 10.1038/ng.439 · DOI · Paper page
  90. Check‐Hayden E, 2008, International genome project launched, Nature, 541, 378, 10.1038/451378b · DOI
  91. 10.1126/science.319.5862.395 · DOI
  92. Gottesman I, 1972, Schizophrenia and genetics: a twin study vantage point
  93. 10.1016/j.jalz.2005.06.003 · DOI · Paper page
  94. 10.1007/s00406-007-1006-x · DOI
  95. 10.1586/erm.09.42 · DOI
  96. 10.1586/erm.10.48 · DOI · Paper page
  97. 10.1016/j.pneurobio.2010.11.005 · DOI
  98. 10.1038/nrd2006 · DOI · Paper page
  99. Oliver KG, 1998, Multiplexed analysis of human cytokines by use of the FlowMetrix system, Clin Chem, 44, 2057, 10.1093/clinchem/44.9.2057 · DOI · Paper page
  100. 10.1373/clinchem.2004.047084 · DOI · Paper page
  101. 10.1021/pr050080b · DOI · Paper page
  102. 10.1186/alzrt49 · DOI · Paper page
  103. 10.1016/j.biopsych.2010.09.020 · DOI
  104. 10.1016/S1474-4422(10)70030-2 · DOI
  105. 10.1038/nature04209 · DOI · Paper page
  106. 10.18632/aging.100413 · DOI · Paper page
  107. 10.1002/ana.21634 · DOI
  108. 10.2741/2677 · DOI
  109. 10.1002/mas.20338 · DOI
  110. 10.1007/s00401-011-0808-0 · DOI · Paper page
  111. ASKesselheim JKarlawish.Biomarkers unbound — the Supreme Court's ruling on diagnostic‐test patents [published online ahead of print May 23 2012]. N Engl Jdoi:10.1056/NEJMp1204164. · doi:10.1056/nejmp1204164
  112. Hampel H, 2011, Special Issue. Biological markers for neurodegenerative diseases, Prog Neurobiol, 95, 491

Cited by

See all 135

Metadata

Authors
Hampel, H., Lista, S., & Khachaturian, Z. S.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2012-07
Volume
8
Issue
4
Pages
312-336
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2058267476
Cited by
135
References
50
FWCI
10.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. https://app.cochat.ai/papers/10.1016/j.jalz.2012.05.2116
The paper
Hampel, H., Lista, S., & Khachaturian, Z. S. (2012). Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.05.2116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.